middle.news
Alterity Therapeutics Secures FDA Green Light for ATH434 Phase 3 Trial in Multiple System Atrophy
9:01am on Tuesday 9th of June, 2026 AEST
•
Biotechnology
Read Story
Alterity Therapeutics Secures FDA Green Light for ATH434 Phase 3 Trial in Multiple System Atrophy
9:01am on Tuesday 9th of June, 2026 AEST
Key Points
FDA endorses Phase 3 study population and dosing
Primary endpoint set as UMSARS Part I with 48% progression slowing
Phase 3 trial initiation planned for year-end 2026
ATH434 holds Fast Track and Orphan Drug designations
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
ALTERITY THERAPEUTICS (ASX:ATH)
OPEN ARTICLE